ArticleBMC public health2025
The burden of chronic respiratory disease in Western Pacific Region from 1990 to 2021: a systematic analysis for the global burden of disease study 2021.
Article in BMC public health, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
Abstract
backgroundChronic respiratory diseases (CRDs) like asthma, chronic obstructive pulmonary disease (COPD), pneumoconiosis, interstitial lung disease (ILD) and pulmonary sarcoidosis pose a major global health challenge. This study thoroughly examines the impact of CRDs in the Western Pacific Region (WPR) from 1990 to 2021.
methodsUsing data from the Global Burden of Disease 2021 study, we evaluated the CRD burden (incidence, prevalence, mortality, disability-adjusted life years (DALYs) in the WPR. The analysis was categorized by age (20-54, ≥ 55), sex, country, CRD subtype, and risk factors, with temporal trends measured by annual and average annual percentage changes (APC, AAPC).
resultsFrom 1990 to 2021, CRD-related DALYs and mortality decreased across all ages, but incidence and prevalence have increased in those aged 20-54 since 2014. Men bear a higher CRD burden than women, though the gap is closing in the 20-54 age group. Air pollution and tobacco are key risk factors, with high body mass index (BMI) becoming more significant, especially for ages 20-54. High-socio-demographic index (SDI) countries show lower mortality and DALYs despite high prevalence and incidence. COPD and asthma are the main CRDs, with asthma most common in ages 20-54 and COPD in those 55 and older. ILD and pulmonary sarcoidosis burdens have risen, particularly in the 55 + group and in medium-high SDI countries like Japan, Australia, and South Korea. Pneumoconiosis is most prevalent in China and South Korea, mainly affecting males aged 20-54.
conclusionsDespite advances in lowering CRD mortality and DALYs in the Western Pacific since 1990, challenges persist, including high COPD and asthma rates, rising ILD and pulmonary sarcoidosis, localized pneumoconiosis, and more young adult cases. Ongoing efforts in tobacco control, air pollution reduction, weight management, and occupational safety are crucial to further decrease the CRD burden.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.